mi.ibarra
Submits third-party assay reports on material purchased directly. Based in Bilbao.
Section 1
Contribution
Purchases material, pays for assays, and submits the resulting reports to the index.
Records submitted
8
n=8
Annotations
0
n=0
Median purity submitted
98.72%
n=8
Suppliers covered
6
n=8
Section 2
Records submitted
A submitter chose to buy this material and to pay for this assay. That choice is the selection mechanism behind the whole index and it is not random.
| Report | Compound | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042461 | Retatrutide | Homopeptide | HOMO-2512-D4932 | Janoshik | 2026-Q2 | 98.72 | 3.51 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2026-043494 | GHRP-6 | BCH | BCH-2603-Y4946 | Janoshik | 2026-Q2 | 99.11 | 5.26 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042918 | Retatrutide | GGPeps | GGPE-2604-X3153 | Janoshik | 2026-Q2 | 98.00 | 5.79 | 107.0 | Buyer-sourced | 0 | PASS |
| AX-2025-019787 | MK-677 (Ibutamoren mesylate) | Homopeptide | HOMO-2506-L4686 | Janoshik | 2025-Q4 | 99.93 | 1.81 | 91.7 | Buyer-sourced | 0 | FAIL |
| AX-2025-018551 | Retatrutide | QYB | QYB-2507-R4727 | Janoshik | 2025-Q4 | 98.73 | 4.19 | 94.0 | Buyer-sourced | 0 | PASS |
| AX-2025-018843 | PT-141 (Bremelanotide) | FGP | FGP-2409-W9076 | PeptideMeter | 2025-Q1 | 99.58 | 5.25 | — | Buyer-sourced | 0 | PASS |
| AX-2024-005294 | CJC-1295 with DAC | BCH | BCH-2406-E5279 | Medutest | 2024-Q4 | 98.52 | 4.72 | 97.4 | Laboratory-retained | 0 | PASS |
| AX-2024-005149 | Tirzepatide | SGN | SGN-2401-K9783 | Janoshik | 2024-Q2 | 98.19 | 4.14 | — | Buyer-sourced | 0 | PASS |